Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the focus areas of neuroscience, cardio-metabolic, influenza vaccines and pancreatic enzymes. We aim for marketing excellence in gastroenterology and men’s and women’s health. Its 2006 sales were EUR 2.6 billion and it employs approximately 10000 people worldwide.
Solvay Pharmaceuticals is one of the core businesses of the Solvay Group. We are headquartered in Brussels (Belgium) and have corporate sites in Hanover (Germany), Marietta (Georgia) and Weesp (The Netherlands). We are active in more than 40 countries. Our products, however, are available in more than 150 countries.
With the acquisition in 2005 of the French pharmaceuticals company Fournier Pharma, we add a 30-years experience in metabolic disease to our cardiovascular expertise, making this cardio-metabolic field our largest franchise.
For over 50 years, Solvay Pharmaceuticals has been working to help people around the world lead healthier, more enjoyable lives. We are committed to finding and developing innovative medicines and optimal health care solutions that allow people to live their lives to the fullest.
Research grant in the field of influenza vaccines